Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion's Shares Spike to Lead Nasdaq

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of molecular diagnostics firm Vermillion rose 23 percent on Monday to close at $8.95, leading all gainers on the Nasdaq for the day.

The reason for the spike is unclear, as the firm didn't disclose any news or file any documents with the US Securities and Exchange Commission. Trading in the firm's shares also was heavy, with 603,100 shares trading hands, compared to its average daily volume of around 128,000.

Vermillion emerged from Chapter 11 bankruptcy protection early in 2010. The firm has since been relisted on Nasdaq and recently inked a new deal with Quest Diagnostics, the company's sales and marketing partner for the OVA1 test.

Vermillion's share price has nearly doubled this month, since its close of $4.79 on Nov. 30.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.